Atlas Trials

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

Clinical trial NCT05896007 · UNKNOWN

Trial details

NCT number
NCT05896007
Sponsor
Ruijin Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
PCNSL
Start date
2023-07-13
Primary completion
2025-12-31
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.